Sanofi Reaches Patent Settlement on Lantus® SoloSTAR®
(Thomson Reuters ONE) -
Sanofi Reaches Patent Settlement on Lantus(®) SoloSTAR(®)
Paris, France - September 28, 2015 - Sanofi announced today that it has reached
a settlement agreement with Eli Lilly and Company ("Lilly"), which addresses
patents on Sanofi's Lantus(® )SoloSTAR(® )(insulin glargine). The agreement
resolves a U.S. patent infringement lawsuit regarding Lilly's pursuit of
regulatory approval for a product that would compete with Lantus SoloSTAR.
Sanofi and Lilly agreed to end that lawsuit and to discontinue similar disputes
worldwide.
Under the agreement, Lilly will pay royalties to Sanofi in exchange for a
license to certain Sanofi patents. In the U.S., Lilly will not sell its insulin
glargine product before December 15, 2016. The agreement does not include Lantus
(vial), Toujeo(®) or combination products. The remaining settlement terms are
confidential.
Sanofi will continue its commitment to develop and deliver innovations for the
more than 387 million people globally living with diabetes.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements"
in Sanofi's annual report on Form 20-F for the year ended December 31, 2014.
Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
Contacts:
Media Relations Investor Relations
Mary Kathryn Steel Sébastien Martel
Tel. : +1 908-989-0726 Tel.: +33 (0)1 53 77 45 45
usmediarelations(at)sanofi.com ir(at)sanofi.com
Click here for high-definition image files for Lantus(® )SoloSTAR(®)
Press release (PDF):
http://hugin.info/152918/R/1954874/711560.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Sanofi via GlobeNewswire
[HUG#1954874]
Unternehmensinformation / Kurzprofil:
Datum: 28.09.2015 - 15:30 Uhr
Sprache: Deutsch
News-ID 423010
Anzahl Zeichen: 5575
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi Reaches Patent Settlement on Lantus® SoloSTAR®"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
